Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21103611 | 0.81 | CYP19A1 (0.44) | CYP19A1CHRM3CYP2C19 | |
| SCHEMBL3345151 | 0.81 | CYP19A1 (0.47) | CYP19A1CHRM3CYP2C19 | |
| Hydrochloric Acid SCHEMBL18954396 | 0.80 | CYP19A1 (0.42) | CYP19A1CHRM3CYP2C19 | |
| Hydrochloric Acid SCHEMBL185528 | 0.80 | CYP19A1 (0.46) | CYP19A1CHRM3CYP2C19 | |
| SCHEMBL4673661 | 0.80 | CYP19A1 (0.50) | CYP19A1CHRM3CYP2C19 | |
| SCHEMBL26357659 | 0.79 | CYP19A1 (0.35) | CYP19A1CHRM3CYP2C19 | |
| Hydrochloric Acid SCHEMBL18954563 | 0.78 | CYP19A1 (0.49) | CYP19A1CHRM3CYP2C19 | |
| SCHEMBL5670027 | 0.76 | CYP2C19 (0.33) | CHRM3CYP2C19 | |
| SCHEMBL21796112 | 0.74 | CYP19A1 (0.35) | CYP19A1CHRM3 | |
| SCHEMBL21305857 | 0.73 | KAT2B (0.36) | CYP19A1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | CYP19A1 2100/4885CHRM3 3877/4885CYP2C19 660/4885 |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | CYP19A1 2100/4885CHRM3 3877/4885CYP2C19 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.